课题基金 / 基金详情

I-Corps: Minimally-invasive Patient-specific Intracardiac Implants

I-Corps: Minimally-invasive Patient-specific Intracardiac Implants
I-Corps:微创患者专用心内植入物
批准号:
2402654
负责人:
Ellen Roche
金额:
$5.0万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2024
资助国家:
美国
项目状态:
已结题
起止时间:
2024-01-15 至 2024-12-31

项目摘要

项目成果

Ellen Roche的其他基金

相似基金

相关文献

中文摘要
翻译
这个i-Corps项目的更广泛的影响/商业潜力是开发一个经导管制造平台。批量生产的现成医用植入物往往无法与人体解剖学的几何、机械和生物学特征相匹配。传统的制造技术通常涉及硬质材料,并被限制在生产有限尺寸和形状的预定义设备。然而,人体解剖学是由柔软和精致的组织组成的,显示出几乎无限的大小和形状,具有复杂的凸起、凹陷、叶和小梁。这种严重的患者-设备不匹配导致植入物不合适、治疗结果不佳、局部组织损伤、愈合反应受损、冗长的术前工作流程以及术前和术后并发症的风险增加。这一愿景的成功实现将代表着医疗制造技术的范式转变,并为患者、提供者和整个医疗系统打开更好的结果之门。这个i-Corps项目是基于一种制造技术的开发,该技术用于直接在人体内产生护理点、微创、针对患者的植入物。设想的工具包利用了材料科学、添加剂制造、基于导管的技术和可植入设备方面的技术和概念上的进步。建议的解决方案将允许临床医生在目标组织部位交付、组装和稳定软生物材料。密实的生物聚合物构建块被流态化,并通过导管输送到可膨胀的生物聚合物封装层。在目标组织处,软构建块被添加到用户定义的3D形状中,该3D形状可以自我修复以匹配宿主解剖的大小和形状。最后,外包裹网状物提供额外的稳定性,以支持长期的结构完整性以及快速的组织愈合和生物整合。总而言之,该系统可以在深解剖位置自下而上地制造无创、个性化的3D医疗植入物,而不需要任何侵入性手术或术前规划和设备选择。该奖项反映了NSF的法定使命,并通过使用基金会的智力优势和更广泛的影响审查标准进行评估,被认为值得支持。
英文摘要
The broader impact/commercial potential of this I-Corps project is the development of a transcatheter manufacturing platform. Mass-produced, off-the-shelf medical implants often fail to match the geometric, mechanical, and biological characteristics of human anatomy. Traditional manufacturing techniques typically involve hard materials and are restricted to producing pre-defined devices in a limited range of sizes and shapes. However, human anatomy is composed of soft and delicate tissues displaying a virtually-limitless range of sizes and shapes with complex convexities, concavities, lobes, and trabeculations. This profound patient-device mismatch leads to poorly-fitting implants, sub-optimal treatment outcomes, local tissue damage, impaired healing responses, lengthy pre-procedural workflows, and elevated risk for peri- and post-procedural complications. Successful realization of this vision would represent a paradigm shift in medical manufacturing technology and open the door for better outcomes for patients, providers, and the overall healthcare system. This I-Corps project is based on the development of a manufacturing technology for point-of-care, minimally-invasive, patient-specific implant generation directly inside the human body. The envisioned toolkit leverages technical and conceptual advancements in materials science, additive manufacturing, catheter-based technologies, and implantable devices. The proposed solution will allow clinicians to deliver, assemble, and stabilize soft biomaterials at the target tissue site. Densely-compacted biopolymeric building blocks are fluidized and delivered via catheter into a distensible biopolymeric encapsulation layer. At the target tissue, the soft building blocks are additively-layered into user-defined 3D shapes that self-heal to match the size and shape of the host anatomy. Finally, the outer encapsulation mesh provides additional stability to support long-term structural integrity and rapid tissue healing and bio-integration. Together, this system could enable bottom-up fabrication of atraumatic, personalized 3D medical implants in deep anatomic locations without any need for invasive surgery or pre-procedural planning and device selection.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CAREER: Hybrid Biorobotic Matrices to Simulate Diaphragmatic and Myocardial Biomechanics
海外基金